ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of therapeutic antibodies and vaccines. The company's core mission is to combat neurodegenerative and other misfolded protein diseases by selectively targeting toxic misfolded proteins at their source. Headquartered in Toronto, Ontario, Canada, ProMIS Neurosciences also maintains offices in Cambridge, Massachusetts, USA.

Utilizing its proprietary target discovery engine, EpiSelect™, ProMIS Neurosciences employs computational modeling to predict and identify Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. This innovative approach enables the development of highly selective antibody therapies and vaccines designed to treat conditions such as Alzheimer's disease (AD) with its lead candidate PMN310, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) with PMN267, and Parkinson's disease (PD) and Multiple System Atrophy (MSA) with PMN442. The company's pipeline also includes vaccine candidates like PMN311 for AD and PMN440 for alpha-synucleinopathies.

Neil Warma assumed the role of interim CEO in January 2024. ProMIS Neurosciences is actively advancing its lead Alzheimer's disease candidate, PMN310, which has received FDA Fast Track designation. The PRECISE-AD Phase 1b clinical trial for PMN310 is fully enrolled, with a blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month unblinded top-line data expected in early 2027. In January 2026, the company successfully closed a PIPE financing round of up to $175 million, which is projected to fund its operations through 2027. This strategic financing supports the company's differentiated approach to selectively target toxic oligomers while aiming to reduce potential side effects such as amyloid-related imaging abnormalities (ARIA).